Relmada Therapeutics, Inc. Common Stock (RLMD) is a publicly traded Healthcare sector company. As of May 21, 2026, RLMD trades at $7.19 with a market cap of $665.00M and a P/E ratio of -4.83. RLMD moved +1.99% today. Year to date, RLMD is +69.50%; over the trailing twelve months it is +1101.01%. Its 52-week range spans $0.24 to $8.00. Analyst consensus is strong buy with an average price target of $15.00. Rallies surfaces RLMD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Relmada Posts $8.5M Q1 Loss, $183M Cash; Launches Phase 3 Depression Trial: Relmada closed Q1 2026 with $183.0 million in cash and equivalents, providing funding into Q2 2027, and narrowed its net loss to $8.5 million versus $10.7 million a year earlier. The company secured Fast Track designation and kicked off its Phase 3 Bridge study of dextromethadone for major depressive disorder, targeting year-end topline data.
| Metric | Value |
|---|---|
| Price | $7.19 |
| Market Cap | $665.00M |
| P/E Ratio | -4.83 |
| EPS | $-1.45 |
| Dividend Yield | 0.00% |
| 52-Week High | $8.00 |
| 52-Week Low | $0.24 |
| Volume | 9 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-57.39M |
| Gross Margin | 0.00% |
3 analysts cover RLMD: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.00.